NE

Neogen Corporation

NEOGHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$870.4M
-2.7% YoY
Net Income
-$7.9M
+99.3% YoY
EBITDA
$170.5M
+118.2% YoY
Free Cash Flow
$38.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 13▲ RSI OversoldRSI 29.6, below 30, stock may be oversold
Oct 5▼ MACD Negative CrossoverHistogram -0.1569, negative momentum
About Neogen Corporation

Part of the healthcare sector, Neogen Corporation (NEOG) is listed under Medical Devices. At a $2.66B market cap, Neogen Corporation ranks as a mid-cap company within healthcare. It operates through Food Safety and Animal Safety segments.

Where NEOG stands vs its 150-day and 200-day moving averages

As of the October 13, 2026 close, NEOG finished 17.07% above its 150-day moving average ($10.25) and 18.34% above its 200-day moving average ($10.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is NEOG overbought or oversold?

At the October 13, 2026 close, NEOG's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.66B
Fwd P/E27.09
EPS$-0.26
Beta1.79
52W Change+96.9%
Dividend Yield0.00%
ROE-2.7%
Analysis

The company holds $172.0M in cash, though total debt stands at $774.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $38.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -2.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $822.4M (2023) to $870.4M (2026).

With a beta above 1.5, NEOG tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Neogen Corporation and its sector.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms